1338961-41-3

Basic information

• Product Name: 1-(2-fluorophenyl)pent-4-en-1-one
• Synonyms: 1-(2-fluorophenyl)pent-4-en-1-one
• CAS NO: 1338961-41-3
• Molecular Weight: 178.206
• Mol File: 1338961-41-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-(2-fluorophenyl)pent-4-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-fluorophenyl)pent-4-en-1-one(1338961-41-3)
• EPA Substance Registry System: 1-(2-fluorophenyl)pent-4-en-1-one(1338961-41-3)

Safety Data

• Hazardous Substances Data: 1338961-41-3(Hazardous Substances Data)

Usage

Type of compound

Organic compound

Carbonyl group

A carbon-oxygen double bond (C=O)

Alkyl groups

Two carbon-containing groups attached to the carbonyl group

Fluorine-substituted phenyl group

A phenyl ring with a fluorine atom attached to the 2nd carbon

5-carbon chain

A linear arrangement of five carbon atoms

Double bond

Between the 4th and 5th carbon atoms in the chain

Fluorine atom

Attached to the 2nd carbon atom of the phenyl group

Molecular weight

180.20 g/mol (calculated from the chemical formula)

Physical state

Likely a liquid or solid at room temperature (based on molecular weight and structure)

Reactivity

Potential reactivity due to the presence of a carbonyl group and a fluorine-substituted phenyl group

Organic synthesis

As a building block or intermediate in the synthesis of more complex organic molecules

Pharmaceutical research

As a potential starting material for the development of new drugs or drug candidates

Further study

Interesting target for research in the field of chemistry due to its unique structure and potential applications

Upstream product

• 393-52-2 2-Fluorobenzoyl chloride 
• 5162-44-7 1-bromo-4-butene 
• 198967-24-7 2-fluoro-N-methoxy-N-methyl-benzamide 
• 7103-09-5 4-but-1-enylmagnesium bromide 
• 445-27-2 2'-Fluoroacetophenone 
• 106-95-6 allyl bromide 

Downstream Products

• 1402742-59-9 C₂₀H₂₅FN₂O₃S 
• 1402742-60-2 C₂₆H₃₂FN₃O₅S 
• 1402743-10-5 C₂₅H₃₂FN₃O₆S 
• 1402743-11-6 C₁₈H₂₆FN₃O₆S 

Relevant articles and documents

Iron-catalyzed carbonylative cyclization of γ,δ-unsaturated aromatic oxime esters to functionalized pyrrolines

Herein, a new method of iron-catalyzed carbonylative cyclization of γ,δ-unsaturated aromatic oxime esters to functionalized pyrrolines has been developed. By using readily available substrates, 32 examples of functionalized pyrrolines were prepared in moderate to good yields. Notably, examples of reduction and cycloaddition reactions of the obtained product were given as well. This journal is

C5-C6-CARBOCYCLIC FUSED IMINOTHIADIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides certain C5-C6-carbocyclic fused iminothiazine dioxide compounds, including compounds Formula (I): and tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, ring A, RA, m, -L1-, ring B, RB, n, q, ring C, RC, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

C5-C6 OXACYCLIC-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula : (I) and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of ring A, ring B, ring C, R2, R3, R4, m, n, p, and -L1- is as defined herein. The novel compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.